Browse NDP

Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00007 Cystine-knot domain
Function

Activates the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptor. Plays a central role in retinal vascularization by acting as a ligand for FZD4 that signals via stabilizing beta-catenin (CTNNB1) and activating LEF/TCF-mediated transcriptional programs. Acts in concert with TSPAN12 to activate FZD4 independently of the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1). May be involved in a pathway that regulates neural cell differentiation and proliferation. Possible role in neuroectodermal cell-cell interaction.

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0001890 placenta development
GO:0007033 vacuole organization
GO:0007423 sensory organ development
GO:0007601 visual perception
GO:0007605 sensory perception of sound
GO:0016055 Wnt signaling pathway
GO:0035426 extracellular matrix-cell signaling
GO:0043010 camera-type eye development
GO:0048608 reproductive structure development
GO:0050953 sensory perception of light stimulus
GO:0050954 sensory perception of mechanical stimulus
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0060041 retina development in camera-type eye
GO:0060070 canonical Wnt signaling pathway
GO:0061298 retina vasculature development in camera-type eye
GO:0061299 retina vasculature morphogenesis in camera-type eye
GO:0061458 reproductive system development
GO:0198738 cell-cell signaling by wnt
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005109 frizzled binding
GO:0005125 cytokine activity
GO:0008083 growth factor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NDP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NDP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NDP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4940.37
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7060.429
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3330.663
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1070.892
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8760.546
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8680.6
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7520.299
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.6120.0379
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.3680.345
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0910.83
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0910.886
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7590.00484
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NDP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NDP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NDP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NDP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NDP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NDP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NDP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNDP
NameNorrie disease (pseudoglioma)
Aliases norrin; EVR2; exudative vitreoretinopathy 2 (X-linked); FEVR; ND; X-linked exudative vitreoretinopathy 2 pro ......
Chromosomal LocationXp11.4-p11.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NDP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.